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Introduction {#sec001}
============

Periodontitis is a complex immuno-inflammatory disease being characterized by periodontal ligament damage and alveolar bone loss, which can lead ultimately to tooth loss. Its complexity arises from the interplay between tooth-associated microbial biofilm and the host\'s immune-inflammatory response \[[@pone.0223800.ref001]\]. Due its prevalence, periodontitis has negative effects on the quality of life of the subjects.

Within inflamed periodontium a plethora of cells (epithelial cells, fibroblasts, leukocytes, osteoblasts, osteoclasts, and dendritic cells) release inflammatory mediators such as cytokines/chemokines (TNF-α, IL1-β, IL-8/CINC-1), as well as prostaglandins (PGE2), and nitric oxide (NO), which promote the breakdown of the tooth supporting tissues \[[@pone.0223800.ref002]\]. Also, it is worth mentioning that reactive oxygen species (ROS) can also play a role in this process \[[@pone.0223800.ref003]\].

The conventional treatment for periodontitis comprises the non-surgical (scaling and root planning) and surgical approaches. Furthemore, adjunct therapy with systemic nonsteroidal anti-inflammatory drugs and antibiotics is sometimes required \[[@pone.0223800.ref004]\]. However, this strategy has attracted a lot of criticisms because the side effects such as emerging of bacterial resistance, gastrointestinal bleeding as well as cardiovascular and renal effects \[[@pone.0223800.ref005]\]. In an attempt to overcome these limitations the search for safer therapeutic agents still continues.

Natural products isolated from plants are considered good alternatives to synthetic chemicals. *Platymiscium floribundum* Vog. (genus Platymiscium and family Fabaceae-Papilionoideae) is a medium sized tree which belongs to the Fabaceae-Papilionoideae family. In the Brazilian Northeast it is popularly known as "sacambu" and "jacaranda-do-litoral" and it has been used in folk medicine as an anti-inflammatory agent. Phytochemical investigation of this genus highlighted flavonoids, isoflavones and coumarins as main constituents \[[@pone.0223800.ref006]--[@pone.0223800.ref007]\].

The use of natural products in the management of periodontitis still lacks preclinical and clinical studies that can prove the efficacy and safety. Thus, the present study was aimed at investigating the unexplored efficacy of *P*. *floribundum* in a rat model of periodontitis. Also, we investigated the putative role of cytokines/chemokines PGE~2~, NO, and oxidative stress in *P*. *floribundum* efficacy. Additional, a systemic evaluation of the sub-chronic toxicity of *P*. *floribundum* was carried out.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

144 female Wistar rats (200--220g) were obtained from the Federal University of Ceara animal research facility. Rats were housed in polypropylene boxes with controlled temperature and 12 h-12 h light dark cycles with free acess to chow diet and water. All animal procedures followed a protocol in compliance with the guidelines from the Brazilian Society of Laboratory Animal Science (SBCAL) and which was approved by a standing Institutional Animal Care and Use Committee at School of Medicine, Federal University of Ceará, Sobral, Ceará, Brazil (Permit number: 05/2015).

Plant material {#sec004}
--------------

*P*. *floribundum* was collected in Acarape, Ceará State, Brazil. A voucher specimen (\#31052) identified by Prof. Edson Paula Nunes is deposited at the Prisco Bezerra Herbarium, Federal University of Ceará, Brazil \[[@pone.0223800.ref008]\]. For this study we used part of the chloroformic extract (2.0 g) obtained from trunk heartwood (8,000.0 g) of *P*. *floribundum*.

Experimental protocol {#sec005}
---------------------

Animals were divided into unchallenged and periodontitis-challenged groups (6 rats each) receiving (*per os*) either *P*. *floribundum* (0.1, 1 or 10 mg/kg) or vehicle (0.9% saline + 0.1% ethanol) 1h before periodontits-challenge and once daily during 11 days.

Periodontitis-challenge was performed, under anesthesia (i.p) (ketamine 90 mg/kg + xylazine 10 mg/kg), by placing a nylon thread (3.0 Nylpoint, Ceará, Brazil) around the second molar \[[@pone.0223800.ref009]\]. On the 11th day, rats were euthanized with an overdose of ketamine/xylazine (300:30mg/kg; i.p.). The maxillae were harvested to analyze the bone loss. *P*. *floribundum* 10 mg/kg was found to be the most effective dose at protecting against alveolar bone loss, and therefore this dose was chosen for hystopathological analyses, and for the quantification in gingival tissues of (1) Myeloperoxidase (MPO) activity, (2) nitrite/nitrate levels, (3) superoxide dismutase-SOD/catalase-CAT levels, (4) TNF-α, IL1-β, IL-8/CINC-1, IL-10, and PGE2 levels (ELISA), and (5) qRT-PCR for TNF-α, IL1-β, COX-2, iNOS, RANK and RANKL. All dosages were done on the 11^th^ day, except for the MPO dosage that was done at the 6^th^ hour.

Determination of bone remodeling {#sec006}
--------------------------------

After 11 days of treatment, the maxillae were harvested and fixed in buffered formalin (10%). After 24 hour, the maxillas were defleshed and stained with methylene blue (1%), fixed in a piece of wax, and photographed. The morphometric analysis of bone resorption was performed using the ImageJ® Software (National Institute of Health, Bethesda, MD, USA), as described previously \[[@pone.0223800.ref010]\]. Further, serum levels of Bone Alkaline Phosphatase (BALP) were quantified as previously described \[[@pone.0223800.ref011]\] for analysis of bone formation.

Histopathological analysis of alveolar bone {#sec007}
-------------------------------------------

The H&E-stained maxillae were semiquantitatively evaluated for the presence of cell infiltrate and osteoclasts, and state of preservation of cement and alveolar process. giving a (0--3) score grade for each of these parameters \[[@pone.0223800.ref009]\].

Scanning Electron Microscopic (SEM) of alveolar bone {#sec008}
----------------------------------------------------

The maxillae were fixed in Karnovisky for at least 6 hours, and then transferred to Cacodylate buffer. They were then cut into a diamond-shaped blade in a medial-distal plane to obtain the maxillary fragment (0.5 × 0.2 cm and 0.5 mm thick). The fragments were left in desiccator drying for 24 h and were assembled into gold dust plating stubs (Quorum Metallizer QT150ES, Quorum Technologies, Laughton, England) for Scanning Electron Microscopy (SEM inspect50, FEI, Hillsboro, Oregon, USA). The analysed region was that between the first and second molar.

MPO activity {#sec009}
------------

MPO activity was analyzed in gingival tissues collected at 6^th^ hour of periodontitis-challenge, as described by Bradley et al. \[[@pone.0223800.ref012]\]. The results were expressed as MPO activity/mg tissue.

NO production {#sec010}
-------------

The total nitrite/nitrate dosage was performed as an indicator of NO production in gingival samples by Griess reaction \[[@pone.0223800.ref013]\]. The values obtained were compared with those obtained for standard curve and expressed in NOx (μM).

SOD and CAT activity assessment {#sec011}
-------------------------------

SOD was measured using a protocol previously described \[[@pone.0223800.ref014]\]. The results are expressed in grams of SOD/mL. CAT activity was performed using a protocol described by Maehly and Chance \[[@pone.0223800.ref015]\]

Cytokines and PGE2 dosage {#sec012}
-------------------------

TNF-α, IL-1β, IL-8/CINC-1, and IL-10 levels were evaluated in gingival samples using commercial kits DuoSet ELISA (R&D Systems Inc., MN, USA). In the same way, the determination of PGE2 was performed by ELISA, using R&D Systems®, Kit Parameter TMPGE2 Assay (catalog PKGE004B, USA kit). Both kits were used according to manufacturer\'s instructions. The results were arranged as pg/mL.

RNA isolation and quantitative real-time PCR {#sec013}
--------------------------------------------

Total RNA was extracted from gingival samples using the TRIzol reagent (Invitrogen, São Paulo, Brazil). The reverse transcription was performed using SuperScript IV Reverse Transcriptase (Invitrogen, São Paulo, Brazil) following the manufacturer's instructions.

Quantitative real-time polymerase chain reaction (qRT-PCR) was performed in StepOne Real-Time PCR thermocycler (Applied Biosystems,Warrington, UK) using SYBRR Green Master Mix (Applied Biosystems, Warrington, UK), as indicated by the manufacturer. The relative gene expression was determined using the 2^-ΔΔCt^ method \[[@pone.0223800.ref016]\], with `GAPDH (S-GGACCAGGTTGTCTCCTGTG/A-CATTGAGAGCAATGCCAGCC)` as the housekeeping gene. The primers pairs used in this study were: `TNF-α (S-CGGGGTGATCGGTCCCAACAAG/ A-GTGGTTTGCTACGACGTGGGC), IL1-β (S-TGCTGTCTGACCCATGTGAG/ A-CCAAGGCCACAGGGATTTTG), COX-2 (S-TCCAGTATCAGAACCGCATTGCCT/A AGCAAGTCCGTGTTCAAGGAGGAT), iNOS (S-AGGCACAAGACTCTGACACC/ A-GGTAGGGTAGAGGAGGGGAG), RANK (S-AGGGAAAACGCTGACAGCTAA/ A-CCAACACAATGGTCCCCTGA), and RANKL (S-GCCAACCGAGACTACGGCAA / A-GAACATGAAGCGGGAGGCG)`.

Toxicity assessment {#sec014}
-------------------

After 11 days of treatment, rats were anesthetized and blood samples were collected from the right ventricle and centrifuged for dosing of total alkaline phosphatase (TALP), creatinine, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Dosages were done following the manufacturer\'s instructions (Labtest®, Lagoa Santa, MG, Brazil). Additionally, after euthanasia, heart, stomach, liver and kidneys were removed for histopathological analysis (H&E).

Statistical analysis {#sec015}
--------------------

All data were normalized using the Shapiro-Wilk normality test. Results were showed as mean±standard error (SEM) or as median, when appropriate. ANOVA followed by the Tukey test or Games-Howell test were used to compare the means and the Kruskal-Wallis and Dunn tests were used to compare the medians. P \<0.05 was considered significant. Analyzes were performed using IBM SPSS Statistics for Windows, Version 20.0. Software Armonk, NY or GraphPad Prism 6, San Diego, CA, USA.

Results {#sec016}
=======

Effect of *P*. *floribundum* on alveolar bone loss {#sec017}
--------------------------------------------------

Administration of *P*. *floribundum* (10 mg/kg) 1 hour before the placement of the ligature and for 11 days resulted in a significant inhibition (p\<0.001) of alveolar bone loss ([Fig 1A](#pone.0223800.g001){ref-type="fig"}), compared to the groups that received only the vehicle (non-treated group). Periodontitis-challenge was associated with alveolar bone resorption, root exposition and loss of interdental contact ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[b\]), when compared to unchallenged group ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[a\]). These findings were confirmed by the histopathological analysis (H&E), which showed an intense inflammatory cell influx, reabsorption of the alveolar bone with partial destruction of the cementum and presence of osteoclasts ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[f\]), receiving median scores of 2 (2--3) ([Table 1](#pone.0223800.t001){ref-type="table"}). *P*. *floribundum* (10 mg/kg) decreased root exposition and loss of interdental contact ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[i\]), when compared to non-treated group ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[b\]). Also, the histopathological analysis (H&E) depicted a discrete inflammatory cellular infiltrate, partial preservation of the alveolar process, preserved cement, and reduction of osteoclasts number ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[j\]), receiving scores from 0--1 ([Table 1](#pone.0223800.t001){ref-type="table"}). These values were statistically different (P \< 0.001), when compared with the non-treated group. When analyzing the region between the first and second molar by using Scanning Electron Microscopy (SEM) in both 65x and 350x magnification, respectively, it can be seen that periodontitis-challenge was associated with an irregular topography ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[g-h\]), when compared to the bone tissue from unchallenged group ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[c-d\]). The rats treated with *P*. *floribundum* (10 mg/kg) ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[k-1\]) showed regular tissue topography, when compared to non-treated group ([Fig 1B](#pone.0223800.g001){ref-type="fig"} \[g-h\]).

![**(A) Effect of *P*. *floribundum* (0.1; 1 or 10 mg/kg) on alveolar bone loss in experimental periodontitis.** Naive: animals without periodontitis; NT: animals subjected to periodontitis and treated with vehicle (0.9% saline + 0.1% ethanol). *P*. *floribundum*: rats submitted to periodontitis and treated with *P*. *floribundum* (0.1; 1 or 10 mg/kg), respectively. Data are shown as mean ± SEM (n = 6 for each treatment). \*P \< 0.000039 *versus* naive; \*\*P \< 0.001 *versus* NT, (ANOVA; Games-Howell). **(B) Effect of *P*. *floribundum* (0.1; 1 or 10 mg/kg) on the macroscopic view (first column), histological aspects (second column), and Scanning Electron Microscopy (SEM) (third columm) of periodontium.** (a--d) normal maxilla (naive), showing the integrity of its components (C---Cementum; D--Dentin, and AB---Alveolar Bone). (e--h) maxilla from rats subjected to periodontitis and receiving only vehicle (0.9% saline + 0.1% ethanol) presenting severe bone resorption, inflammatory infiltrate in the gingiva and periodontal ligament, extensive destruction of cementum, total resorption of the alveolar process (f), and irregularity in the bone tissue (g---h). (i--l) maxilla from rats subjected to periodontitis and treated with *P*. *floribundum* (10 mg/kg) showing discrete cellular influx and preservation of cementum and alveolar process (j) and regular tissue topography (k--l). Black arrows indicate alveolar bone resorption. HE magnification (100x); MEV magnification 65x: c, g, and k; MEV magnification 350x: d, h, and i.](pone.0223800.g001){#pone.0223800.g001}

10.1371/journal.pone.0223800.t001

###### Effect of *P*. *floribundum* on histopathology (H&E) in the maxilla from rats subjected to periodontitis.

![](pone.0223800.t001){#pone.0223800.t001g}

                                                                                                                                         *P*. *floribundum*                              
  -------------------------- ---------- ------------------------------------------------ ----------------------------------------------- ----------------------------------------------- -------------------------------------------------
  **Median and Variation**   0 (0--0)   2 (2--3) [\*](#t001fn001){ref-type="table-fn"}   2 (1--3)[\*](#t001fn001){ref-type="table-fn"}   1 (0--2)[\*](#t001fn001){ref-type="table-fn"}   0 (0--1)[\*\*](#t001fn002){ref-type="table-fn"}

\*P \<0.001 versus naive

\*\*P \<0.001 *versus* non-treated group (NT) (Kruskal-Wallis; post hoc Dunn's Test).

Also, periodontitis-challenge was associated with a decrease in BALP levels, which was prevented by the *P*. *floribundum* (10 mg/kg) injection, when compared with the non-treated group ([Fig 1C](#pone.0223800.g001){ref-type="fig"}).

Effect of *P*. *floribundum* on MPO activity {#sec018}
--------------------------------------------

A subset of rats was euthanized at the 6^th^ hour for analysis of MPO activity, where it was found a significant increase in MPO activity, when compared to naive group ([Fig 2](#pone.0223800.g002){ref-type="fig"}). *P*. *floribundum* (10 mg/kg) decreased MPO activity, when compared with to non-treated group ([Fig 3](#pone.0223800.g003){ref-type="fig"}).

![Effect of *P*. *floribundum* on the serum alkaline phosphatase levels.\
Data represent the mean ± SEM of six animals for each group. \*p\<0.001 *versus* naive; \*\*p\<0.012 versus non-tretaed (NT) (ANOVA; post hoc Games-Howell).](pone.0223800.g002){#pone.0223800.g002}

![Effect of *P*. *floribundum* (10mg/kg) on gingival myeloperoxidase (MPO) activity.\
Data are shown as mean ± SEM (n = 6 for each treatment). \*P \< 0.000023 versus naive; \*\*P \< 0.01046 versus non-treated NT, (ANOVA; Tukey).](pone.0223800.g003){#pone.0223800.g003}

Periodontitis-challenged group displayed a significant increase in nitrite/nitrate levels (P \< 0.05) ([Fig 4A](#pone.0223800.g004){ref-type="fig"}). Also, it was found a significant reduction in SOD (P\<0.0003) and CAT (P \< 0.007) levels, when compared to naive group ([Fig 4B and 4C](#pone.0223800.g004){ref-type="fig"}). *P*. *floribundum* (10 mg/kg) decreased nitrite/nitrate levels (P \< 0.0317) ([Fig 4A](#pone.0223800.g004){ref-type="fig"}), and it increased both markers for oxidative stress (SOD and CAT) (P \< 0.013 and P \< 0.002, respectively) ([Fig 4B and 4C](#pone.0223800.g004){ref-type="fig"}), when compared with to non-treated group.

![(A) **Effect of *P*. *floribundum* (10mg/kg) on gingival nitrite/nitrate levels (NOx).** Data are shown as mean ± SEM (n = 6 for each treatment). \*P \< 0. 0015 versus naive; \*\*P \< 0. 0317 *versus* non-treated (NT) (ANOVA; Tukey). (B) **Effect of *P*. *floribundum* (10mg/kg) on gingival SOD (B) and CAT (C) levels.** Data are shown as mean ± SEM (n = 6 for each treatment). \* P \< 0.0003 *versus* naive; \*\* p\< 0.013 *versus* NT (ANOVA; Tukey). \*P \< 0.007 *versus* naive; \*\*P \< 0.002 *versus* non-treated (NT) (ANOVA; Games-Howell).](pone.0223800.g004){#pone.0223800.g004}

Effects of *P*. *floribundum* on both cytokines and PGE2 levels {#sec019}
---------------------------------------------------------------

Periodontits-challenge was associated with increased levels of TNF-α (P \< 0.00001), IL-1β (P \< 0.000001), and IL-8/CINC-1 (P \< 0.017), when compared to the naive group ([Fig 5A--5C](#pone.0223800.g005){ref-type="fig"}). Still, it was observed a significant (P \< 0.01) decrease in gingival levels of IL-10, when compared to naive group ([Fig 5D](#pone.0223800.g005){ref-type="fig"}). Also, it was found significantly (P\<0.0001) higher gingival PGE-2 levels in non-treated rats, when compared to the naive group. *P*. *floribundum* (10 mg/kg) injection decreased the levels of both proinflammatory cytokines and PGE2, and increased IL-10 levels ([Fig 5E](#pone.0223800.g005){ref-type="fig"}).

![**Effects of *P*. *floribundum* on TNF-α (A), IL-1β (B), IL-8/CINC-1 (C), IL-10 (D), and PGE2 levels in gingival tissues.** Data are shown as mean ± SEM (n = 6 for each treatment). \*P \< 0.00001 *versus* Naive and \*\*P \< 0.001 *versus* NT for TNF-α; \*P \< 0.017 *versus* Naive and \*\*P \< 0.05 *versus* NT for IL-8; \*P \< 0.000001 *versus* Naive and \*\*P \< 0.0000001 *versus* NT for IL-1β; \*P \< 0.000 *versus* Naive and \*\*P \< 0.004 *versus* NT for PGE2; \*P \< 0,01 *versus* Naive and \*\*P \< 0.02 *versus* NT for IL-10 (ANOVA; Games-Howell; post hoc Tukey).](pone.0223800.g005){#pone.0223800.g005}

Effects of *P*. *floribundum* on the mRNA levels of TNF-α, IL-1β, COX-2, iNOS, RANK, and RANK-L {#sec020}
-----------------------------------------------------------------------------------------------

Periodontitis-challenged group expressed a significant increase in the mRNA levels of TNF-α (P\<0.001), IL-1β (P\<0.0000001), COX-2 (P\<0.000004), iNOS (p\< 0.007), RANK (P\<0.036), and RANK-L (P\<0.05), when compared to naive group ([Fig 6A--6F](#pone.0223800.g006){ref-type="fig"}). *P*. *floribundum* (10 mg/kg) injection significantly reduced the mRNA levels of TNF-α, IL-1β, COX-2, iNOS, RANK (P\<0.036), and RANK-L, when compared to the vehicle group (P \< 0.001; P \< 0.0000001; P \< 0.000004; P \< 0.001; P \< 0.039; and P \< 0.036, respectively) ([Fig 6A--6F](#pone.0223800.g006){ref-type="fig"}).

![Effect of *P*. *floribundum* (10mg/kg) on the mRNA levels of TNF-α, IL-1β, COX-2, iNOS, RANK, and RANK-L in gingival tissues from rats subjected to periodontitis.\
Data are shown as mean ± SEM (n = 6 for each treatment). **A.** \* P \< 0.001 *versus* Naive; \*\*P \< 0.001 versus NT. **B.** \*P \< 0.0000001 *versus* Naive; \*\*P \< 0.0000001 *versus* NT. **C.** \* P \< 0.000004 *versus* Naive; \*\*P \< 0.000004 *versus* NT. **D.** \* P \< 0.007 *versus* Naive; \*\* P \< 0.001 *versus* NT. **E.** \*P \< 0.036 *versus* Naive; \*\* P \< 0.039 *versus* NT. **F.** \* P \< 0.05 *versus* Naive; \*\* P \< 0.036 *versus* NT (ANOVA; Tukey; Games-Howell, respectively).](pone.0223800.g006){#pone.0223800.g006}

Evaluation of *P*. *floribundum* toxicity {#sec021}
-----------------------------------------

During the 11 days of treatment with *P*. *floribundum* the animals do not showed any signs of toxicity or mortality. The serum levels of Total Alkaline Phosphatase (TALP), creatinine, as well as serum levels of liver enzymes (AST and ALT) were unchanged, when compared to non-treated animals ([Table 2](#pone.0223800.t002){ref-type="table"}).

10.1371/journal.pone.0223800.t002

###### Evaluation of treatment with *P*. *floribundum* on biochemical parameters in rats submitted to induction of periodontitis.

![](pone.0223800.t002){#pone.0223800.t002g}

                                                                                *P*. *floribundum*   
  ---------------------------- --------------- ---------------- --------------- -------------------- ---------------
  Parameters                   Naive           NT               0.1             1                    10
  Total Alkaline Phosphatase   87.86 ± 9.79    84.54 ± 6.62     87.30 ± 7.40    64.93 ± 4.32         65.60 ± 4.96
  Creatinine                   11.56 ± 0.26    12.73 ± 0.55     12.60 ± 0.67    13.60 ± 0.24         13.72 ± 0.68
  AST (U/I)                    114.4 ± 7.262   123.8 ± 7.667    103.6 ± 3.125   99.93 ± 4.581        102.2 ±2.615
  ALT (U/I)                    38.67 ± 2.539   33.46 ± 0.8512   40.00 ± 3.36    37.50 ± 2.61         38.38 ± 1.840

Data represent the mean ± S.E.M. (ANOVA; Tukey\'s).

The histopathological analysis of the liver and kidney from animals treated with *P*. *floribundum* (10 mg/kg) depicted reversible and harmless changes, including: mild cellular swelling, few haemorrhagic areas, and areas of discrete congestion ([Fig 7D and 7F](#pone.0223800.g007){ref-type="fig"}), when compared to the vehicle treated group. However, all these histological changes are considered reversible. The heart and gastric mucosa of the animals did not show any histopathological changes ([Fig 7B--7H](#pone.0223800.g007){ref-type="fig"}).

![Photomicrographs of organs from rats subjected to periodontitis and treated with *P*. *floribundum* (10mg/kg).\
**(A)** Heart, **(C)** Liver, **(E)** Kidney, and **(G)** Stomach from non-treated (NT) group (rats receiving only vehicle). **(B)** Heart, **(D)** Liver, **(F)** Kidney, and **(H)** Stomach from rats treated *P*. *floribundum* (10mg/kg). Black circles indicate cellular swelling, few hemorrhagic areas (D), areas of discrete congestion (F). Magnification 100x.](pone.0223800.g007){#pone.0223800.g007}

Discussion {#sec022}
==========

Herein we have demonstrated the anti-inflammatory and anti-resorptive effect of *P*. *floribundum* in a ligature-induced periodontitis in rats. In this study *P*. *floribundum* (10 mg/kg) reduced alveolar bone loss and increased the serum levels of BALP, an isoenzyme of alkaline phosphatase considered a marker of bone formation. Furthermore, *P*. *floribundum* (10mg/kg) decreased MPO activity, TNF-α, IL1-β, IL-8/CINC-1, and PGE2 gingival levels, oxidative stress, and transcription of TNF-α, IL1-β, COX-2, iNOS, RANK and RANKL genes, while elevated IL-10 gingival levels. Additional, the animals did not show signs of toxicity throughout the experimental course.

Several species of Fabaceae family shows pharmacological activities, thus being a promising source of new bioactive products. Many of these plants are used in popular medicine showing effects such as expectorant, analgesic, treatment of asthma and abdominal pain \[[@pone.0223800.ref017]--[@pone.0223800.ref018]\]. Although *P*. *floribundum* is popularly used as an anti-inflammatory \[[@pone.0223800.ref019]\], the literature has few studies concerning its mechanism of action. In this regard, phytochemical investigations demonstrated the induction of apoptosis by flavonoids from *P*. *floribundum* in HL-60 human leukemia cells \[[@pone.0223800.ref006]\]. Further, it was reported *P*. *floribundum* antifungal, DNA-damaging and anticholinesterasic activities \[[@pone.0223800.ref007]\]. The use of natural products in the management of periodontitis still lacks preclinical and clinical studies that can prove its efficacy and safety. *P*. *floribundum* was chosen to be studied because it has been used in the Brazilian Northeast in folk medicine as an anti-inflammatory agent and no previous pharmacology study was reported yet. Indeeed, the present study is the first demonstration of both efficacy and safety of *P*. *floribundum* as anti-inflammatory agent.

BALP has been implicated in bone formation \[[@pone.0223800.ref020]\]. In the present study, *P*. *floribundum* (10 mg/kg) increased serum levels of BALP, which suggests that it may promote bone formation and prevent alveolar bone loss. *P*. *floribundum* have some secondary metabolites such as flavonoids, isoflavones, and coumarins \[[@pone.0223800.ref007]\], and some authors have shown that these metabolites are able to decrease inflammatory mediators during bone resorption \[[@pone.0223800.ref021]\].

MPO activity was used as a marker of inflammatory cell infiltrates (especially neutrophils) in the inflamed periodontium. According to Palm et al. \[[@pone.0223800.ref022]\], MPO may be used as a biomarker of periodontitis and high saliva MPO concentrations may suggest periodontal tissue destruction. In the present study, periodontitis-challenge was associated with a significant increase in MPO activity. *P*. *floribundum* (10 mg/kg) decreased MPO acivity, suggesting that the efficacy of *P*. *floribundum* may be associated with reduction of neutrophil influx.

The periodontitis-associated microbiota can activate resident and recruited inflammatory cells to secrete proinflammatory cytokines/chemokines, which stimulate bone resorption by stimulating the activity of osteoclasts \[[@pone.0223800.ref023]\]. Indeed, these cytokines increase the recruitment and activity of these cells through improved production of a key osteoclastogenic factor, the Receptor Activator of Nuclear Factor κ B Ligand (RANK-L) and favor bone damage \[[@pone.0223800.ref002]\]. Also, some authors have suggested the potential involvement of both pro- and anti-inflammatory cytokines in the regulation of the chronic inflammatory periodontitis. In fact, our research group recently showed that ligature-induced periodontitis in rats was related to a significant decrease in gingival levels of IL-10, an anti-inflammatory cytokine \[[@pone.0223800.ref024]\] In the preset study, *P*. *floribundum* (10mg/kg) decreased TNF-α, IL1-β, and IL-8/CINC-1 gingival levels and transcription of TNF-α, IL1-β, RANK and RANKL genes, while elevated IL-10 gingival levels, which suggestes that the protective effect of *P*. *floribundum* may be related to the modulation of both pro- and anti-inflammatory cytokines levels in gingival tissue.

The biosynthesis of PGE2 is close related to pro-inflammatory cytokines activity. Some authors showed that the biosynthesis of PGE2 is increased in inflamed gingiva and this synthesis is enhanced by pro-inflammatory cytokines (TNF-α, IL-1β), creating a vicious circle in states of inflammatory osteolysis, promoting alveolar bone loss \[[@pone.0223800.ref002]\]. Sánchezz et al. \[[@pone.0223800.ref025]\] suggested the salivary levels of both IL-1β and PGE2 as biomarkers of periodontal status. Our research group recently demonstrated that periodontitis-challenge in rats is associated with both high gingival PGE-2 levels and increased periodontal immunostaining for its processing enzyme COX-2 \[[@pone.0223800.ref026]\]. In the present study, we demonstrated that ligature-induced periodontitis rats expressed a significant increase in the mRNA of COX-2. *P*. *floribundum* reduced both PGE2 levels and the transcription of COX-2 genes in inflamed gingival tissues, which suggests that its antiresorptive effects are, at least in part, related to inhibition of COX-2.

Both preclinical and clinical trials support the hypothesis that the inhibition of prostaglandins with nonsteroidal anti-inflammatory drugs (NSAIDs) slows periodontitis progression \[[@pone.0223800.ref027]\]. Once selective COX-2 inhibitors had a better risk-benefit ratio than the standard NSAIDs, we performed the histophatological analysis of the gastric mucosa of *P*. *floribundum* treated-rats, which showed no evidence of macroscopic and microscope alterations. Our present data is significant considering that gastric mucosal damage is a common side effect of NSAIDs.

Since NO has been shown to have dual effects during inflammatory processes, it would not be different in the periodontitis. While some authors suggested that NO plays an important role in the destruction of periodontal tissues \[[@pone.0223800.ref028]\], Martins et al. \[[@pone.0223800.ref029]\] demonstrated that NO donors decreased inflammation and bone loss in a model of periodontits in rats. Pro-inflammatory cytokines participate in the amplification of the inflammatory response during periodontitis disease by the transcription of the inducible nitric oxide synthase (iNOS) that results in the production of high amounts of NO \[[@pone.0223800.ref030]\] In the present study, periodontitis-challenged rats displayed a significant increase in nitrite/nitrate levels and expressed a significant increase in the mRNA of iNOS in gingival tissue, which was reduced by the treatment with *P*. *floribundum* (10 mg/kg).

In order to keep the ROS levels in a normal range, enzymatic mechanisms such as SOD and CAT are activated continuously. Here we demonstrated that rats with periodontitis showed a significant reduction in both SOD and CAT levels, when compared to naive rats. *P*. *floribundum* increased both markers for oxidative stress. These data are in accordance with previous results of our group showing the antioxidant effect of natural extracts from *Stemodia maritima* L. and *Calendula offinalis* \[[@pone.0223800.ref024]\], \[[@pone.0223800.ref031]\]

Considering the growing interest in natural products, research concerning not only the efficacy but also the toxicity profile of these products is very encouraged \[[@pone.0223800.ref032]--[@pone.0223800.ref033]\]. Hence, in the present study, we performed biochemical analysis in peripheral blood from rats 11 days after daily injection of *P*. *floribundum*. Further, we evaluated the integrity (H&E) of heart, liver and kidneys from rats that received *P*. *floribundum*. Neither biochemical analysis nor the histopathological ones revealed any signs of toxicity.

In conclusion, *P*. *floribundum* reduces inflammatory markers associated with periodontitis, such as bone loss, pro-inflammatory cytokines, and oxidative stress. Our findings suggest that this natural product-based, may act in different pathways involved in inflammatory process during periodontitis. Thus, *P*. *floribundum* may offer a huge of possibilities for planning a supportive periodontal therapy, being promising to the oral health care industry.
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The authors demonstrated protective effect of the extract from a tree P. floribundum Vog reduced inflammatory markers of periodontitis in rats including bone loss, cytokines, antioxidant and oxidative stress implicating the use in periodontal therapy.
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ANSWER: Fig. 1B panels are labeled and we show with black arrows the bone loss observed under periodontitis condition and treatment conditions (Please, see the revised version of the manuscript with tracked changes).
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The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Although the manuscript is interesting in the inhibitory effects of the extracts from Platymiscium Floribundum Vog in on periodontitis there are serious problems. The authors should be addressing them.

ANSWER: We really appreciate the interest of the reviewer in our data. We tried to address all the comments raised.

1\) The paper indicated that the tree extract inhibited the inflammation and alveolar bone resorption. However, it is unclear how the inhibitory mechanism on bone resorption is. Is the extract directly or indirectly osteoclasts or osteoblasts? If the extract is mediated by anti-inflammation and resulting in the bone resorbing inhibition what cytokine is mainly inhibition? The authors should be speculated the inhibitory mechanism in discussion section in according to the known mechanism of the extract on anti-inflammation.

ANSWER: In order to make our answer clear enough we will answer this question considering the three issues raised by the Reviewer \#1, as follows:

\(A\) Is the extract directly or indirectly osteoclasts or osteoblasts?

\(B\) If the extract is mediated by anti-inflammation and resulting in the bone resorbing inhibition what cytokine is mainly inhibition?

\(C\) The authors should be speculated the inhibitory mechanism in discussion section in according to the known mechanism of the extract on anti-inflammation.

\(A\) Is the extract directly or indirectly osteoclasts or osteoblasts?

ANSWER: It has been shown that in the bone remodeling cycle, bone formation is coupled with bone resorption to maintain the bone health (Florencio-Silva et al., Biomed Res Int. (2015) 2015:421746). The success of this process involves a complex cross-talk between bone cells (osteoblasts and osteoclasts) and immune system cells (T lymphocytes, macrophages, and neutrophils) (Dar HY et al., Front. Biosci. (Landmark Ed). (2018) 23:464-492). During bone loss diseases, such as periodontitis, inflammation promotes a disruption in the balance between bone formation/bone degradation in towards of resorption (Hienz et al., J Immunol Res. 2015; 2015:615486). In response to inflammation-induced bone loss, neutrophils are usually the first cell type migrating to damage sites. Activated neutrophils can secrete a plethora of inflammatory mediators, such as, chemokines, cytokines, reactive oxygen species, prostaglandins, and small molecules (nitric oxide), which are able to act as immunomodulatory factors, then amplifying the inflammatory response, leading to the occurrence of bone loss (Amarasekara et al., J Immunol Res. (2015) 2015:832127; Domazetovic et al., Clin Cases Miner Bone Metab. (2017) 14(2): 209-216; Lisowska et al., Drug Des Devel Ther. (2018) 12:1753-1758; Kalyanaraman et al., Nitric Oxide. (2018) 76:62-70). On the other hand, anti-inflammatory agents, such as, P. floribundum may positively disturb this process in favour of bone formation, which may be beneficial during bone disorders related to inflammation, suggesting its use as a potential bone-protecting agent.

In the present study we tried to understand the underlying mechanisms of the anti-inflammatory action of P. floribundum by using an in vivo system to assess both soft and hard tissue destruction. Our research group has shown in last years that the inflammation-induced bone loss during periodontitis in rats is a complex process, which involves many players (Freitas, et al., Biomedicine & pharmacotherapy (2018) 98:863-872; Teixeira et al., Frontiers in Physiology (2017) 8:988; Sousa et al., Journal of Periodontology (2016) 87:1206-1216). Indeed, in the present study P. floribundum reduced bone loss and this action was due to its broad anti-inflammatory action including decreased MPO activity, TNF-α, IL1-β, IL-8/CINC-1, and PGE2 gingival levels, oxidative stress, and transcription of TNF-α, IL1-β, COX-2, iNOS, RANK and RANKL genes, while increasing both IL-10 gingival levels and bone alkaline phosphatase (BALP) serum levels. Considering our current data we can speculate that the inhibitory mechanism on bone resorption promoted by P. floribundum in the present study may be indirectly on both bone cells (osteoclasts and osteoblasts), and it might be related to the anti-inflammatory action of P. floribundum, including: reducing of both neutrophils infiltrate (evaluated by the levels of MPO), and the amount of pro-inflammatory mediators, while increasing the synthesis of IL-10, an anti-inflammatory cytokine.

Therefore, understanding the communication between the immune systems and the skeletal is important for the discovery and development of novel anti-reabsortive drugs and it will clarify the known signal transduction pathways.

\(B\) If the extract is mediated by anti-inflammation and resulting in the bone resorbing inhibition what cytokine is mainly inhibition?

The network of inflammatory cytokines produced during inflammation induces an uncoupling of bone formation and resorption, resulting in significant bone loss (Amarasekara et al., J Immunol Res. (2015) 2015:832127). Ferreira et al (1993) (Br J Pharmacol. 110(3):1227-31) developed the concept that, in rats, inflammatory stimuli cause mechanical hypernociception by a well-defined sequential release of cytokines. These authors showed that among cytokines, TNF-α has a pivotal role in the development of inflammatory hyperalgesia. Indeed, the first cytokine released is TNF-α, which triggers the release of IL-6/IL-1β and cytokine-induced neutrophil chemoattractant-1 (CINC-1) (human IL-8-related chemokine), which is responsible for stimulation of the synthesis of prostaglandins (Cunha et al., Br. J. Pharmacol. (1991) 104: 765--767; Cunha et al., Br. J. Pharmacol. (1992) 107: 660--664; Lorenzetti et al., Eur. Cytokine Network (2002)13: 456--461).

During periodontitis cytokine involvement is well known, and these molecules, particularly tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) may amplify the inflammatory response, causing tissue destruction and bone loss. TNF-α and IL-1β are the first to appear in periodontitis pathways and they are associated with inflammatory cell migration (Hoare et al., Mediators Inflamm. (2019) 2019:1029857). Also, the release of TNF-α and IL-1β during periodontitis activates osteoblasts and osteoclasts to produce COX2-mediated prostaglandin E2 (PGE2), triggering bone resorption (Yu et al., J Periodontal Res. (2016) 51(1):38-49). Further, preclinical and clinical trials have proven the protective effect of both TNF-α and IL-1β inhibitors on periodontitis (Lima et al., J. Periodontol. (2004) 75: 156--162; Holmlund et al., J Clin. Periodontol. (2004) 31: 475--482). Therefore, the inhibition of cytokine production or action appears to constitute a real target for a new therapeutic approach to control the inflammatory bone diseases such as periodontitis.

Thus, considering the previous data showing the central role of TNF-α during inflammatory response by activating the cascade of cytokine release, which consequently amplifies the degree of inflammation, and its involvement during periodontitis, we may speculate that TNF-α could be the main cytokine involved in the anti-inflammatory efficacy of P. floribundum.

\(C\) The authors should be speculated the inhibitory mechanism in discussion section in according to the known mechanism of the extract on anti-inflammation.

Answer: Although P. floribundum is popularly used as an anti-inflammatory \[19\], the literature has few studies concerning its mechanism of action. In this regard, phytochemical investigations demonstrated the induction of apoptosis by flavonoids from P. floribundum in HL-60 human leukemia cells (reference number 6 - Militão et al., Life Sci. (2006); 78 (20): 2409-2417). Further, it was reported P. floribundum antifungal, DNA-damaging and anticholinesterasic activities (reference number 7 - Cardoso-Lopes Rev. Bras. Farmacogn. 2008; 18: 655-660). The use of natural products in the management of periodontitis still lacks preclinical and clinical studies that can prove its efficacy and safety. P. floribundum was chosen to be studied because it has been used in the Brazilian Northeast in folk medicine as an anti-inflammatory agent and no previous pharmacology study was reported yet. Indeed, the present study is the first demonstration of both efficacy and safety of P. floribundum as an anti-inflammatory agent. In keeping with this assumption, we included a sentence in the discussion section mentioning this issue (Please, see the revised version of the manuscript with tracked changes, lines 391-405).

2\) The authors should try to use the combination of some inhibitors or neutralized antibodies such as COX2 inhibitor, NOS inhibitor or anti-TNFalpha antibody with the extract in periodontitis model animal.

ANSWER: We really appreciate the interest of the reviewer in our protocol elaboration. The main idea of our research group is to develop a natural product, which may provide a better risk/benefit ratio in the treatment of periodontitis. Herein, we carefully draw a suggestion that P. floribundum has a regulatory role in inflammation-induced bone loss during periodontitis, reducing the main inflammatory mediators that orchestrates bone loss. Indeed, P. floribundum decreased TNF-α and PGE2 gingival levels, and transcription of TNF-α, COX-2, and iNOS genes. Therefore, considering these data, and keeping in mind the 3R Principle (Russel and Burch, 1959), which suggests the reduction of the animal numbers whenever possible, we did not consider the possibility of use the combination of some inhibitors or neutralized antibodies such as COX2 inhibitor, NOS inhibitor or anti-TNFalpha antibody with the extract in periodontitis model animal.

3\) p18, line 297: Is FAT correct, not but TALP?

ANSWER: The acronym FAT is not correct and it was replaced by the correct acronym TALP. Please, see the revised version of the manuscript with tracked changes (line 349).
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